⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SCNX News
Scienture Holdings, Inc. Common Stock
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
globenewswire.com
SCNX
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
globenewswire.com
SCNX
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
globenewswire.com
SCNX
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
globenewswire.com
SCNX
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
accessnewswire.com
DGXX
DYAI
STRT
GAME
ACNT
RNXT
DCGO
BOSC
SCNX
ELWT
MOB
VELO
FLUX
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
globenewswire.com
SCNX
iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
accessnewswire.com
DYAI
STRT
GAME
ACNT
RNXT
DCGO
BOSC
SCNX
ELWT
MOB
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
globenewswire.com
SCNX
SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
globenewswire.com
SCNX
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
globenewswire.com
SCNX